Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL8370700 | 1.00 | USP2 (0.53) | USP2SLCO1B1PAX8PDE4ALMNA | |
| Acetic Acid SCHEMBL7572044 | 1.00 | USP2 (0.53) | USP2SLCO1B1PAX8PDE4ALMNA | |
| Acetic Acid SCHEMBL489053 | 1.00 | USP2 (0.53) | USP2SLCO1B1PAX8PDE4ALMNA | |
| Pyruvate SCHEMBL17296438 | 0.94 | USP2 (0.48) | USP2SLCO1B1PAX8PDE4ALMNA | |
| Bicarbonate SCHEMBL20888 | 0.94 | USP2 (0.55) | USP2SLCO1B1PAX8PDE4ALMNA | |
| SCHEMBL2227363 | 0.92 | LMNA (0.52) | USP2SLCO1B1PAX8PDE4ALMNA | |
| SCHEMBL8586304 | 0.92 | LMNA (0.52) | USP2SLCO1B1PAX8PDE4ALMNA | |
| SCHEMBL420278 | 0.92 | LMNA (0.52) | USP2SLCO1B1PAX8PDE4ALMNA | |
| SCHEMBL1548302 | 0.92 | LMNA (0.52) | USP2SLCO1B1PAX8PDE4ALMNA | |
| SCHEMBL22963142 | 0.92 | LMNA (0.52) | USP2SLCO1B1PAX8PDE4ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8361990-B2 | Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20120021046-A1 | GLUCOSAMINE AND GLUCOSAMINE/ANTI-INFLAMMATORY MUTUAL PRODRUGS, COMPOSITIONS, AND METHODS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2012-01-26 | — | — | US | claimed |
| US-20080020997-A1 | Glucosamine and Glucosamine/Anti-Inflammatory Mutual Prodrugs, Compositions, and Methods | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | US | claimed |
| EP-1742534-A2 | GLUCOSAMINE AND GLUCOSAMINE/ANTI-INFLAMMATORY MUTUAL PRODRUGS, COMPOSITIONS, AND METHODS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-01-17 | — | — | EP | claimed |
| WO-2005116086-A2 | GLUCOSAMINE AND GLUCOSAMINE/ANTI-INFLAMMATORY MUTUAL PRODRUGS, COMPOSITIONS, AND METHODS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2005-12-08 | — | — | WO | claimed |
| US-20050101563-A1 | Method and compositions for the treatment and prevention of pain and inflammation | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | US | claimed |
| EP-1416940-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND GLUCOSAMINE | Pharmacia Corporation (US) | 2004-05-12 | — | — | EP | claimed |
| EP-1416941-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND CHONDROITIN SULFATE | Pharmacia Corporation (US) | 2004-05-12 | — | — | EP | claimed |
| US-20030114416-A1 | Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | PHARMACIA CORPORATION | 2003-06-19 | — | — | US | claimed |
| US-20030114418-A1 | Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor | PHARMACIA CORPORATION | 2003-06-19 | — | — | US | claimed |
| WO-2003015797-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND GLUCOSAMINE | PHARMACIA CORPORATION (US) | 2003-02-27 | — | — | WO | claimed |
| WO-2003015799-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND CHONDROITIN SULFATE | PHARMACIA CORPORATION (US) | 2003-02-27 | — | — | WO | claimed |
| WO-2002080934-A1 | A COMPOSITION COMPRISING GLUCOSAMINE FOR TREATING ANGIOGENESIS-DEPENDENT DISEASES | ANGIOLAB INC. (KR) | 2002-10-17 | — | — | WO | claimed |
| CN-115501172-A | Gel formulations for topical drug delivery | 丹麦技术大学 | 2022-12-23 | — | — | CN | disclosed |
| CN-107249570-B | Gel formulations for topical drug delivery | 丹麦技术大学 | 2022-08-09 | — | — | CN | disclosed |
| EP-3220887-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | Technical University of Denmark (DK) | 2017-09-27 | — | — | EP | disclosed |
| US-20030114416-A1 | Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | PHARMACIA CORPORATION | 2003-06-19 | — | — | US | disclosed |
| WO-2003015797-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND GLUCOSAMINE | PHARMACIA CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003015799-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND CHONDROITIN SULFATE | PHARMACIA CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2002080934-A1 | A COMPOSITION COMPRISING GLUCOSAMINE FOR TREATING ANGIOGENESIS-DEPENDENT DISEASES | ANGIOLAB INC. (KR) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114416-A1 | Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | CSGALNACT1, PTGS2, PTGS1 | USP2 1417/4885SLCO1B1 1694/4885PAX8 3639/4885 |
| US-20120021046-A1 | GLUCOSAMINE AND GLUCOSAMINE/ANTI-INFLAMMATORY MUTUAL PRODRUGS, COMPOSITIONS, AND METHODS | GNE, UGGT1, OGT | USP2 2642/4885SLCO1B1 1431/4885PAX8 2406/4885 |
| US-20080020997-A1 | Glucosamine and Glucosamine/Anti-Inflammatory Mutual Prodrugs, Compositions, and Methods | GNE, UGGT1, OGT | USP2 2642/4885SLCO1B1 1431/4885PAX8 2406/4885 |
| US-20050101563-A1 | Method and compositions for the treatment and prevention of pain and inflammation | PTGES2, PTGS2, PTGS1 | USP2 1617/4885SLCO1B1 1437/4885PAX8 3727/4885 |
| US-20030114418-A1 | Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor | PTGS2, PTGS1, UGGT1 | USP2 2161/4885SLCO1B1 1938/4885PAX8 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.